Weekly Paclitaxel Infusion as Salvage Therapy in Ovarian Cancer

References

• Greenlee R.T., Murray T., Bolden S., Wingo P.A. Cancer statistics, 2000. CA Cancer J. Clin. 2000; 50(1)7–33
   PubMed Web of Science ®Google Scholar
• Ozols R.F. Chemotherapy for ovarian cancer. Semin. Oncol. 1999; 26(6 Suppl. 18)34–40
   PubMed Web of Science ®Google Scholar
• McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., Clarke-Pearson D.L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [see comments]. N. Engl. J. Med. 1996; 334(1)1–6
   PubMed Web of Science ®Google Scholar
• Cannistra S.A. Cancer of the ovary [published erratum appears in N. Engl. J. Med. Feb 10 1994, 330 (6), 448] [see comments]. N. Engl. J. Med. 1993; 329(21)1550–1559
   PubMed Web of Science ®Google Scholar
• Markman M., Bookman M.A. Second-line treatment of ovarian cancer. Oncologist 2000; 5(1)26–35
   PubMedGoogle Scholar
• Rowinsky E.K., Cazenave L.A., Donehower R.C. Taxol: a novel investigational antimicrotubule agent. J. Natl Cancer Inst. 1990; 82(15)1247–1259
   PubMed Web of Science ®Google Scholar
• Trimble E.L., Adams J.D., Vena D., Hawkins M.J., Friedman M.A., Fisherman J.S., Christian M.C., Canetta R., Onetto N., Hayn R. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J. Clin. Oncol. 1993; 11(12)2405–2410
   PubMed Web of Science ®Google Scholar
• Thigpen J.T., Blessing J.A., Ball H., Hummel S.J., Barrett R.J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J. Clin. Oncol. 1994; 12(9)1748–1753
   PubMed Web of Science ®Google Scholar
• Trope C., Hogberg T., Kaern J., Bertelsen K., Bjorkholm E., Boman K., Himmelmann A., Horvath G., Jacobsen A., Kuoppola T., Vartianen J., Lund B., Onsrud M., Puistola U., Salmi T., Scheistroen M., Sandvei R., Simonsen E., Sorbe B., Tholander B., Westberg R. Long-term results from a phase II study of single agent paclitaxel (taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience. Ann. Oncol. 1998; 9(12)1301–1307
   PubMed Web of Science ®Google Scholar
• Zanotti K.M., Belinson J.L., Kennedy A.W., Webster K.D., Markman M. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol. Oncol. 2000; 79(2)211–215
   PubMed Web of Science ®Google Scholar
• Abu-Rustum N.R., Aghajanian C., Barakat R.R., Fennelly D., Shapiro F., Spriggs D. Salvage weekly paclitaxel in recurrent ovarian cancer. Semin. Oncol. 1997; 24(5 Suppl. 15)S15-62–S15-67
   Web of Science ®Google Scholar
• Fennelly D., Aghajanian C., Shapiro F., O'Flaherty C., McKenzie M., O'Connor C., Tong W., Norton L., Spriggs D. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J. Clin. Oncol. 1997; 15(1)187–192
   PubMed Web of Science ®Google Scholar
• Markman M., Baker M.E., Hall J.B., Spitz D.L. Phase 2 trial of weekly single agent paclitaxel (P) in platinum (PLAT) and paclitaxel-refractory ovarian cancer (OC) [abs #1567]. Proc. Am. Soc. Clin. Oncol. 2000; 19(396a)
   Google Scholar
• Anderson H., Bowman K., Ridderheim M., Rosenberg P., Sorbe B., Puistola U., Horvath G. An updated analysis of a randomized study of single agent paclitaxel (P) given weekly vs every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy [abs #1505]. Proc. Am. Soc. Clin. Oncol. 2000; 19(380a)
   Google Scholar
• Rustin G.J., Nelstrop A.E., McClean P., Brady M.F., McGuire W.P., Hoskins W.J., Mitchell H., Lambert H.E. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J. Clin. Oncol. 1996; 14(5)1545–1551
   PubMed Web of Science ®Google Scholar
• Pettersson F. Annual Report on the Results of Treatment in Gynecologic Cancer, FIGO 1994. International Federation of Gynecology and Obstetrics, Stockholm, 83–102
   Google Scholar
• Muggia F.M., Hainsworth J.D., Jeffers S., Miller P., Groshen S., Tan M., Roman L., Uziely B., Muderspach L., Garcia A., Burnett A., Greco F.A., Morrow C.P., Paradiso L.J., Liang L.J. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 1997; 15(3)987–993
   PubMed Web of Science ®Google Scholar
• Creemers G.J., Bolis G., Gore M., Scarfone G., Lacave A.J., Guastalla J.P., Despax R., Favalli G., Kreinberg R., Van Belle S., Hudson I., Verweij J., ten Bokkel Huinink W.W. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study [see comments]. J. Clin. Oncol. 1996; 14(12)3056–3061
   PubMed Web of Science ®Google Scholar
• Rose P.G., Blessing J.A., Mayer A.R., Homesley H.D. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 1998; 16(2)405–410
   PubMed Web of Science ®Google Scholar
• Markman M., Blessing J.A., Moore D., Ball H., Lentz S.S. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol. Oncol. 1998; 69(3)226–229
   PubMed Web of Science ®Google Scholar
• Shapiro J.D., Millward M.J., Rischin D., Michael M., Walcher V., Francis P.A., Toner G.C. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol. Oncol. 1996; 63(1)89–93
   PubMed Web of Science ®Google Scholar
• Markman M., Iseminger K.A., Hatch K.D., Creasman W.T., Barnes W., Dubeshter B. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report [see comments]. Gynecol. Oncol. 1996; 62(1)4–6
   PubMed Web of Science ®Google Scholar
• Nardi M., Aloe A., De Marco S., Cognetti F., Iacovelli A., Atlante G., Calabresi F. Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. Am. J. Clin. Oncol. 1997; 20(3)230–232
   PubMed Web of Science ®Google Scholar
• Blom R., Palm N., Simonsen E. Paclitaxel (taxol) monotherapy in the treatment of progressive and recurrent ovarian carcinoma after platinum-based chemotherapy. Acta Oncol. 1996; 35(6)733–736
   PubMed Web of Science ®Google Scholar
• Mayerhofer K., Kucera E., Zeisler H., Speiser P., Reinthaller A., Sevelda P. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy [see comments]. Gynecol. Oncol. 1997; 64(1)109–113
   PubMed Web of Science ®Google Scholar
• Seidman A.D., Hudis C.A., Albanel J., Tong W., Tepler I., Currie V., Moynahan M.E., Theodoulou M., Gollub M., Baselga J., Norton L. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J. Clin. Oncol. 1998; 16(10)3353–3361
   PubMed Web of Science ®Google Scholar
• Omura G.A., Brady M.F., Delmore J.E., Long H.J., Look K.Y., Averette H.E., Wadler S., Spiegel G. A randomized trial of paclitaxel (T) at 2 doses levels and filgrastim (G; GCS-F) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study [abs #755]. Proc. Am. Soc. Clin. Oncol. 1996; 15(280)
   Google Scholar
• Belotti D., Vergani V., Drudis T., Borsotti P., Pitelli M.R., Viale G., Giavazzi R., Taraboletti G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 1996; 2(11)1843–1849
   PubMed Web of Science ®Google Scholar
• Klauber N., Parangi S., Flynn E., Hamel E., D'Amato R.J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997; 57(1)81–86
   PubMed Web of Science ®Google Scholar
• Lau D.H., Xue L., Young L.J., Burke P.A., Cheung A.T. Paclitaxel (taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother. Radiopharm. 1999; 14(1)31–36
   PubMed Web of Science ®Google Scholar
• Loffler T.M., Freund W., Lipke J., Hausamen T.U. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. Semin. Oncol. 1996; 23(6 Suppl. 16)32–34
   PubMed Web of Science ®Google Scholar